What happened
Humana Inc. (NYSE: HUM) put 95% of its Medicare Advantage members into plans rated 4 stars or above for 2027. The comparable share was 20% for 2026.
That is a 75-percentage-point increase, or 4.75 times the prior coverage share. Humana Inc. (NYSE: HUM) also said its normalized Stars revenue per member exceeded its top-quartile goal, defined as 10% above the peer median.
Why it matters
The ratings affect 2028 Medicare Advantage quality bonus payments. Moving most members above the four-star line restores an important revenue opportunity after the prior year's sharp coverage decline.
Humana's framework counts incremental retained rebates at 3.5, 4 and 4.5 stars, plus the quality bonus received at four stars. That is why crossing the threshold can change per-member economics even before membership moves.
The operating consequence is delayed but real. Better bonus economics can support richer member benefits, stronger plan competitiveness or earnings. Humana Inc. (NYSE: HUM) said it expects a 2028 benefit and affirmed at least $9.00 of adjusted earnings per share for 2026.
The filing also narrows the bullish claim. Actual 2028 Stars revenue will depend on membership, contract mix, risk scores, benchmarks and rebates. Humana Inc. (NYSE: HUM) expects some top-quartile outperformance to be one-time and plans to use that portion for one-time investments and shareholder returns.
Ratings do not directly prove lower medical costs. The standing case still requires better underwriting margins and operating cash flow. A higher score can improve revenue while claims costs, pricing or regulation absorb the benefit.
Browse: stock research on every company OptimistFi covers
What's next
Humana Inc. (NYSE: HUM) plans a December 10 investor update. The decisive test comes later, when management quantifies the 2028 benefit alongside expected membership and contract mix.
The case strengthens further if bonus revenue reaches margins and cash flow without weaker benefits or higher medical costs. It weakens if the ratings improvement proves temporary, gets competed away or fails to offset underwriting pressure.
More from OptimistFi
- HUM stock: the Humana thesis, its status and the next test to watch
- Prudential Financial, Inc. (NYSE: PRU) Faces Longer Japan Sales Ban
- NVIDIA Corporation (NASDAQ: NVDA) Commits $1 Billion to US Science
- Dividendology Explains Hess Midstream LP (NYSE: HESM)'s EBITDA Reset
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- Humana Inc. (NYSE: HUM) October 9, 2026 Form 8-K — Final 2027 Star Ratings, normalized top-quartile comparison, 2028 benefit framing, December investor update, security identity and affirmed 2026 adjusted EPS guidance.
- Humana Inc. (NYSE: HUM) October 2, 2025 Form 8-K — Prior-year comparison showing 20% of members in plans rated 4 stars or above for 2026.
- Centers for Medicare & Medicaid Services 2027 Star Ratings fact sheet — Published October 8, 2026. Confirms the ratings appear for 2027 open enrollment and affect 2028 Medicare Advantage quality bonus payments.
- Photo: Medical professional consults a senior patient by SHVETS production — Stock photo taken May 16, 2021. It does not depict a Humana facility, employee, member or the October 2026 ratings event.
- Photo license: Pexels License — Pexels permits free editorial website use and modification. The photograph is used without alteration; responsive display may crop it.
Read the full OptimistFi thesis on Humana Inc.: https://optimistfi.com/stocks/HUM
See what would break the Humana Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Humana Inc. investment case, its status and the next test to watch live on the Humana Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
